Sinopharm Group Financials
| X2S Stock | EUR 2.64 0.04 1.54% |
Sinopharm |
Understanding current and past Sinopharm Group Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Sinopharm Group's financial statements are interrelated, with each one affecting the others. For example, an increase in Sinopharm Group's assets may result in an increase in income on the income statement.
Sinopharm Group Stock Summary
Sinopharm Group competes with AmerisourceBergen, Cardinal Health, Henry Schein, Shanghai Pharmaceuticals, and Sinopharm Group. Ltd., together with its subsidiaries, engages in the wholesale and retail of pharmaceutical and medical devices and healthcare products in the Peoples Republic of China. The company was founded in 2003 and is headquartered in Shanghai, the Peoples Republic of China. SINOPHARM GRP operates under Medical Distribution classification in Germany and is traded on Frankfurt Stock Exchange. It employs 108370 people.| Instrument | Germany Stock View All |
| Exchange | Frankfurt Exchange |
| ISIN | CNE100000FN7 |
| Business Address | Sinopharm Group Building, |
| Sector | Healthcare |
| Industry | Medical Distribution |
| Benchmark | Dow Jones Industrial |
| Website | www.sinopharmgroup.com.cn |
| Phone | 86 21 2305 2666 |
| Currency | EUR - Euro |
You should never invest in Sinopharm Group without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Sinopharm Stock, because this is throwing your money away. Analyzing the key information contained in Sinopharm Group's financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
Sinopharm Group Key Financial Ratios
There are many critical financial ratios that Sinopharm Group's investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that Sinopharm Group reports annually and quarterly.| Return On Equity | 0.13 | |||
| Return On Asset | 0.0364 | |||
| Beta | 0.72 | |||
| Z Score | 1.0 | |||
| Last Dividend Paid | 0.75 |
Sinopharm Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Sinopharm Group's current stock value. Our valuation model uses many indicators to compare Sinopharm Group value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Sinopharm Group competition to find correlations between indicators driving Sinopharm Group's intrinsic value. More Info.Sinopharm Group Co is rated fifth in return on equity category among its peers. It is rated below average in return on asset category among its peers reporting about 0.28 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Sinopharm Group Co is roughly 3.62 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Sinopharm Group's earnings, one of the primary drivers of an investment's value.Sinopharm Group Systematic Risk
Sinopharm Group's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Sinopharm Group volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Beta measures systematic risk based on how returns on Sinopharm Group correlated with the market. If Beta is less than 0 Sinopharm Group generally moves in the opposite direction as compared to the market. If Sinopharm Group Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Sinopharm Group is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Sinopharm Group is generally in the same direction as the market. If Beta > 1 Sinopharm Group moves generally in the same direction as, but more than the movement of the benchmark.
Sinopharm Group December 22, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Sinopharm Group help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Sinopharm Group Co. We use our internally-developed statistical techniques to arrive at the intrinsic value of Sinopharm Group Co based on widely used predictive technical indicators. In general, we focus on analyzing Sinopharm Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Sinopharm Group's daily price indicators and compare them against related drivers.
| Downside Deviation | 2.95 | |||
| Information Ratio | 0.1721 | |||
| Maximum Drawdown | 18.93 | |||
| Value At Risk | (3.20) | |||
| Potential Upside | 4.47 |
Complementary Tools for Sinopharm Stock analysis
When running Sinopharm Group's price analysis, check to measure Sinopharm Group's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sinopharm Group is operating at the current time. Most of Sinopharm Group's value examination focuses on studying past and present price action to predict the probability of Sinopharm Group's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sinopharm Group's price. Additionally, you may evaluate how the addition of Sinopharm Group to your portfolios can decrease your overall portfolio volatility.
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data |